Urinary Glycosaminoglycans: Characterization and Quantification

Naima Fdil; Es-Said Sabir

doi:10.1007/978-1-0716-2946-8_5

Urinary Glycosaminoglycans: Characterization and Quantification

Methods Mol Biol. 2023:2619:61-69. doi: 10.1007/978-1-0716-2946-8_5.

Authors

Naima Fdil¹, Es-Said Sabir²

Affiliations

¹ Metabolic Platform, Biochemistry Laboratory, Faculty of Medicine, Cadi Ayyad University, Moroccan Association for Inherited Metabolic Diseases, Marrakech, Morocco. nfdil@yahoo.fr.
² Metabolic Platform, Biochemistry Laboratory, Faculty of Medicine, Cadi Ayyad University, Moroccan Association for Inherited Metabolic Diseases, Marrakech, Morocco.

PMID: 36662462
DOI: 10.1007/978-1-0716-2946-8_5

Abstract

The growing body of evidence supports the potential of using urinary glycosaminoglycans (uGAGs) levels as biomarkers to guide diagnosis and as predictive biomarkers of treatment efficacy. Recently, studies have shown that, in addition to MPS, the prognosis and treatment of cancers and viral infections, including COVID-19, are enabled by characterization and/or traits by GAGs. Reliable and accessible detection and assay protocols of urinary GAGs are therefore of great support for laboratory workers and clinicians. Here we describe a semiquantitative and quantitative urinary glycosaminoglycans determination using 1,9-dimethylmethylene blue (DMB) and the characterization of uGAGs using thin layer chromatography (TLC).

Keywords: 1,9-Dimethylmethylene blue; Glycosaminoglycans; Thin layer chromatography.

MeSH terms

Biomarkers
COVID-19* / diagnosis
Chromatography, Thin Layer
Glycosaminoglycans
Humans
Mucopolysaccharidoses* / diagnosis

Substances

Glycosaminoglycans
Biomarkers